Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...
PMLive

Medicus Pharma completes patient enrolment for basal cell carcinoma trial

Medicus Pharma has announced the completion of patient enrollment for its phase 2 SKNJCT-003 trial, evaluating the safety and ...
clinicaladvisor.com

Gorlin basal cell nevus syndrome: diagnosis and management

Those with NBCCS should be monitored for the development of NBCCS-related complications and should receive treatment for postnatal tumors and odontogenic keratocysts. Individuals with NBCCS should be ...
Seeking Alpha

Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million

Patidegib, an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome, if approved by the FDA Phase 3 ...

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

THE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026 AND REQUEST END-OF-PHASE 2 (EOP2) ...